Patents Assigned to B.R.A.I.N. Biotechnology Research and Information Network AG
-
Patent number: 10829833Abstract: The invention provides a process of isolating or enriching a heavy metal present in a liquid medium. The process comprising the following steps: (a) incubating a suspension containing (i) particulate scrap metal, household waste and/or industrial waste containing a heavy metal in elemental form and (ii) biomass comprising a bacterium, or a combination of two or more bacteria, capable of binding the heavy metal; (b) separating the biomass having bound heavy metal from the suspension of step (a); and (c) isolating the heavy metal from the biomass separated in step (b).Type: GrantFiled: March 30, 2016Date of Patent: November 10, 2020Assignee: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Stephen Gos, Andrea Christiansen, Xin Lu, Guido Meurer, Yvonne Tiffert, Esther Gabor, Benedikt Hoffmann, Martin Langer
-
Patent number: 10000438Abstract: The present invention relates to the use of compounds which are capable of attenuating skin irritation when they are applied to the skin. Skin irritation can be caused, inter alia, by ingredients of cosmetic or pharmaceutical compositions and/or environmental irritants. In particular, the present invention relates to compounds having the property of antagonizing the activation of the transient receptor potential (TRP) ankyrin 1 (TRPA1) ion channel and the use of said compounds as soothing agents. Such compounds can be used in many fields, particularly in personal-care products, cosmetics, textile and packaging products, pharmaceutical compositions, medical devices, and foodstuffs. The present invention further relates to products and/or pharmaceutical compositions containing said compounds. The present invention also relates to the use of the compounds described herein for the modulation of the taste of a food product.Type: GrantFiled: August 2, 2016Date of Patent: June 19, 2018Assignee: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Michael Krohn, Dirk Sombroek
-
Publication number: 20180105482Abstract: The present invention relates to the use of compounds which are capable of attenuating skin irritation when they are applied to the skin. Skin irritation can be caused, inter alia, by ingredients of cosmetic or pharmaceutical compositions and/or environmental irritants. In particular, the present invention relates to compounds having the property of antagonizing the activation of the transient receptor potential (TRP) ankyrin 1 (TRPA1) ion channel and the use of said compounds as soothing agents. Such compounds can be used in many fields, particularly in personal-care products, cosmetics, textile and packaging products, pharmaceutical compositions, medical devices, and foodstuffs. The present invention further relates to products and/or pharmaceutical compositions containing said compounds. The present invention also relates to the use of the compounds described herein for the modulation of the taste of a food product.Type: ApplicationFiled: August 2, 2016Publication date: April 19, 2018Applicant: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Michael KROHN, Dirk SOMBROEK
-
Publication number: 20180073100Abstract: The invention provides an assay for identifying a bacterium capable of binding elemental heavy metal, comprising the following steps: cultivating a test bacterium in a suitable first culture medium; immersing at least a surface portion of a test tool into the first culture medium for a second predetermined period of time, said surface portion being coated by elemental heavy metal, respectively; removing said test tool from said first culture medium and optionally rinsing the test tool; contacting a second culture medium with the surface portion coated by elemental heavy metal of said test tool removed in the previous step; and identifying the test bacterium as being capable of binding elemental heavy metal from growth of the test bacterium in said second culture medium.Type: ApplicationFiled: March 30, 2016Publication date: March 15, 2018Applicant: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Stephen Gos, Andrea Christiansen, Xin Lu, Guido Meurer, Yvonne Tiffert, Esther Gabor, Benedikt Hoffmann, Martin Langer
-
Publication number: 20180057910Abstract: The invention provides an assay for identifying a bacterium capable of binding elemental heavy metal, comprising the following steps: cultivating a test bacterium in a suitable first culture medium; immersing at least a surface portion of a test too! into the first culture medium for a second predetermined period of time, said surface portion being coated by elemental heavy metal, respectively; removing said test tool from said first culture medium and optionally rinsing the test tool; contacting a second culture medium with the surface portion coated by elemental heavy metal of said test tool removed in the previous step; and identifying the test bacterium as being capable of binding elemental heavy metal from growth of the test bacterium in said second culture medium.Type: ApplicationFiled: July 8, 2016Publication date: March 1, 2018Applicant: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Stephen Gos, Andrea Christiansen, Xin Lu, Guido Meurer, Yvonne Tiffert, Esther Gabor, Benedikt Hoffmann, Martin Langer
-
Patent number: 9585865Abstract: The present invention relates to the use of compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. In particular, the present invention relates to the use of compounds modulating TRPM8, and optionally to the use of compounds selectively exhibiting agonist activity at the TRPM8 channel. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs, but also in pharmaceutical composition products, cosmetics, textile products and packaging products. The present invention further relates to products containing such compounds and to the medical use of such compounds.Type: GrantFiled: December 8, 2014Date of Patent: March 7, 2017Assignee: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Michael Krohn, Holger Zinke
-
Publication number: 20160340288Abstract: The present invention relates to the use of compounds which are capable of attenuating skin irritation when they are applied to the skin. Skin irritation can be caused, inter alia, by ingredients of cosmetic or pharmaceutical compositions and/or environmental irritants. In particular, the present invention relates to compounds having the property of antagonizing the activation of the transient receptor potential (TRP) ankyrin 1 (TRPA1) ion channel and the use of said compounds as soothing agents. Such compounds can be used in many fields, particularly in personal-care products, cosmetics, textile and packaging products, pharmaceutical compositions, medical devices, and foodstuffs. The present invention further relates to products and/or pharmaceutical compositions containing said compounds. The present invention also relates to the use of the compounds described herein for the modulation of the taste of a food product.Type: ApplicationFiled: August 2, 2016Publication date: November 24, 2016Applicant: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Michael KROHN, Dirk SOMBROEK
-
Patent number: 9440993Abstract: The present invention relates to the use of compounds which are capable of attenuating skin irritation when they are applied to the skin. Skin irritation can be caused, inter alia, by ingredients of cosmetic or pharmaceutical compositions and/or environmental irritants. In particular, the present invention relates to compounds having the property of antagonizing the activation of the transient receptor potential (TRP) ankyrin 1 (TRPA1) ion channel and the use of said compounds as soothing agents. Such compounds can be used in many fields, particularly in personal-care products, cosmetics, textile and packaging products, pharmaceutical compositions, medical devices, and foodstuffs. The present invention further relates to products and/or pharmaceutical compositions containing said compounds. The present invention also relates to the use of the compounds described herein for the modulation of the taste of a food product.Type: GrantFiled: May 11, 2012Date of Patent: September 13, 2016Assignee: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Michael Krohn, Dirk Sombroek
-
Patent number: 9404080Abstract: The present invention relates to proliferating human taste cells, wherein the cells are the cells deposited under the DSMZ deposit accession number DSM ACC3169 or taste cells derived thereof. The present invention further relates to the proliferating human taste cells of the invention for use in research. Further, the present invention relates to in vitro methods for analyzing the signalling response of taste cells to a molecule involved in taste signalling, in vitro methods of identifying agents capable of eliciting a taste response in taste cells as well as in vitro methods of identifying modulators of taste signalling.Type: GrantFiled: April 25, 2013Date of Patent: August 2, 2016Assignee: B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AGInventors: Andreas Hochheimer, Michael Krohn
-
Patent number: 9353386Abstract: The present invention relates to a host cell having an elevated expression or activity of an enzyme as compared with the parent cell from which it has been derived, said enzyme having lactoyl-CoA reductase activity. Furthermore, provided is a method of producing lactaldehyde and/or 1,2-propanediol, said method comprising culturing said host cell and/or utilizing said enzyme to produce said compound.Type: GrantFiled: June 15, 2012Date of Patent: May 31, 2016Assignee: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Daniel Koch, Guido Meurer, Jürgen Eck
-
Publication number: 20160008297Abstract: The present invention primarily relates to the use of one or more specific compounds and/or one or more respective salt(s) thereof for preventing, reducing or alleviating itchy skin condition(s), and/or as PAR-2 antagonist. Furthermore, the present invention relates to compositions (products or, respectively, formulations), in particular for topical administration, preferably cosmetic or pharmaceutical compositions, in particular for preventing, reducing or alleviating one or more itchy skin conditions and/or for providing a PAR-2 antagonistic effect, comprising or consisting of an effect amount of such compound(s) and/or salt(s) and one or more cosmetically and/or pharmaceutically acceptable carriers.Type: ApplicationFiled: August 23, 2012Publication date: January 14, 2016Applicant: B.R.A.I.N. Biotechnology Research And Information Network AGInventors: Gerhard SCHMAUS, Michael KROHN, Dirk SOMBROEK, Lars Ole HAUSTEDT, Grit KLUGE, Oskar KOCH, Antje KÖHLER
-
Publication number: 20150094365Abstract: The present invention relates to the use of compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. In particular, the present invention relates to the use of compounds modulating TRPM8, and optionally to the use of compounds selectively exhibiting agonist activity at the TRPM8 channel. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs, but also in pharmaceutical composition products, cosmetics, textile products and packaging products. The present invention further relates to products containing such compounds and to the medical use of such compounds.Type: ApplicationFiled: December 8, 2014Publication date: April 2, 2015Applicant: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Michael KROHN, Holger ZINKE
-
Patent number: 8993743Abstract: The present invention relates to a nucleic acid molecule encoding a chimeric protein having the biochemical activity of a surface active protein, wherein said chimeric protein comprises: (a) an N-terminal portion of a first surface active protein, wherein the N-terminal portion is devoid of between 0 and 10 of the most N-terminal amino acids of the mature first surface active protein; and, C-terminally thereof, (b) a C-terminal portion of a second surface active protein, wherein the C-terminal portion is devoid of between 0 and 10 of the most C-terminal amino acids of the mature second surface active protein. The present invention further relates to a vector, a non-human host and a method for the production of a chimeric protein having the biochemical activity of a surface active protein. In addition, the present invention relates to a chimeric protein encoded by the nucleic acid molecule of the invention and a composition comprising the chimeric protein.Type: GrantFiled: February 18, 2011Date of Patent: March 31, 2015Assignee: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Guido Meurer, Esther Gabor, Anke Bachert, Jürgen Eck
-
Publication number: 20140178953Abstract: The present invention relates to a host cell having an elevated expression or activity of an enzyme as compared with the parent cell from which it has been derived, said enzyme having lactoyl-CoA reductase activity. Furthermore, provided is a method of producing lactaldehyde and/or 1,2-propanediol, said method comprising culturing said host cell and/or utilizing said enzyme to produce said compound.Type: ApplicationFiled: June 15, 2012Publication date: June 26, 2014Applicant: B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AGInventors: Daniel Koch, Guido Meurer, Jürgen Eck
-
Patent number: 8758730Abstract: The present invention provides the use of surface active proteins, especially class I and class II hydrophobins, in topically applied pharmaceutical formulations. The invention is particularly directed to topically applied pharmaceutical products for enhancing the penetration to achieve a transungual delivery of a prophylactically and/or therapeutically effective amount of an active ingredient (drug) to a patient (including animals and humans) into and/or through a nail, of the animal or human body, in order to treat one or more of a variety of diseases or disorders. Related embodiments of the invention are also disclosed.Type: GrantFiled: February 19, 2010Date of Patent: June 24, 2014Assignee: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Andreas Buthe, Andreas Hafner, Franz Kaufmann, Babette Fiedler, Guido Meurer, Gordon Bradley
-
Patent number: 8679829Abstract: The present invention relates to a sulfolobus expression vector comprising: (a) sulfolobus origin of replication; (b) the genes encoding the structural proteins and the site-specific integrase of SSV1, SSV2 or pSSVx, operatively linked to expression control sequences and a packaging signal; (c) one or more selectable marker gene(s), operatively linked to sulfolobus expression control sequences; and (d) a sulfolobus promoter followed 3? by a restriction enzyme recognition site or a multiple cloning site for insertion of a gene of interest and optionally a 3? regulatory element. Moreover, the present invention relates to a shuttle vector comprising the sequences of the expression vector of the invention and additional sequences for propagation and selection in E. coli, wherein the additional sequences comprise (a) an E. coli on of replication; and (b) a marker for selection in E. coli.Type: GrantFiled: June 2, 2004Date of Patent: March 25, 2014Assignee: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Christa Schleper, Melanie Jonuscheit, Jürgen Eck, Frank Niehaus, Sonja-Verena Albers, Sabrina Froels
-
Publication number: 20140080842Abstract: The present invention relates to the use of compounds which are capable of attenuating skin irritation when they are applied to the skin. Skin irritation can be caused, inter alia, by ingredients of cosmetic or pharmaceutical compositions and/or environmental irritants. In particular, the present invention relates to compounds having the property of antagonizing the activation of the transient receptor potential (TRP) ankyrin 1 (TRPA1) ion channel and the use of said compounds as soothing agents. Such compounds can be used in many fields, particularly in personal-care products, cosmetics, textile and packaging products, pharmaceutical compositions, medical devices, and foodstuffs. The present invention further relates to products and/or pharmaceutical compositions containing said compounds. The present invention also relates to the use of the compounds described herein for the modulation of the taste of a food product.Type: ApplicationFiled: May 11, 2012Publication date: March 20, 2014Applicant: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Michael Krohn, Dirk Sombroek
-
Patent number: 8623810Abstract: We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds.Type: GrantFiled: March 3, 2010Date of Patent: January 7, 2014Assignee: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Frank Niehaus, Jürgen Eck, Renate Schulze, Michael Krohn
-
Publication number: 20130345300Abstract: The present invention relates to the use of compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. In particular, the present invention relates to the use of compounds modulating TRPM8, and optionally to the use of compounds selectively exhibiting agonist activity at the TRPM8 channel. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs, but also in pharmaceutical composition products, cosmetics, textile products and packaging products. The present invention further relates to products containing such compounds and to the medical use of such compounds.Type: ApplicationFiled: March 8, 2012Publication date: December 26, 2013Applicant: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Michael Krohn, Holger Zinke
-
Patent number: RE47528Abstract: We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds.Type: GrantFiled: January 25, 2018Date of Patent: July 23, 2019Assignee: B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AGInventors: Frank Niehaus, Jürgen Eck, Renate Schulze, Michael Krohn